Search

Your search keyword '"McMurray, J. J. V."' showing total 314 results
Start Over Author "McMurray, J. J. V."
314 results on '"McMurray, J. J. V."'

4. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial

Author

Butt, J, primary, Lu, H, additional, Kondo, T, additional, Bachus, E, additional, De Boer, R A, additional, Hernandez, A, additional, Inzucchi, S, additional, Jhund, P S, additional, Kosiborod, M, additional, Lam, C, additional, Martinez, F, additional, Shah, S J, additional, Vaduganathan, M, additional, Solomon, S D, additional, and Mcmurray, J J V, additional

Published
2023
Full Text
View/download PDF

5. Effect of empagliflozin on CMR-estimated pulmonary capillary wedge pressure in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)

Author

Osmanska, J, primary, Lee, M M Y, additional, Berry, C, additional, Brooksbank, K J M, additional, Mangion, K, additional, Roditi, G, additional, Woodward, R, additional, Jhund, P S, additional, Mark, P B, additional, Mcmurray, J J V, additional, Sattar, N, additional, Petrie, M C, additional, Docherty, K F, additional, and Campbell, R T, additional

Published
2023
Full Text
View/download PDF

6. Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER

Author

Wang, X, primary, Lam, C S P, additional, Claggett, B, additional, Miao, M, additional, Shah, S J, additional, Jhund, P S, additional, Desai, A S, additional, Chiang, C, additional, Pham, V N, additional, Han, Y, additional, Kitakaze, M, additional, Langkilde, A M, additional, Mcmurray, J J V, additional, Solomon, S D, additional, and Vaduganathan, M, additional

Published
2023
Full Text
View/download PDF

7. Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

Author

Wang, X, primary, Chatur, S, additional, Lu, H, additional, Claggett, B, additional, Skali, H, additional, Vaduganathan, M, additional, Minamisawa, M, additional, Inciardi, R M, additional, Shah, A M, additional, Packer, M, additional, Pitt, B, additional, Rouleau, J, additional, Pfeffer, M A, additional, Mcmurray, J J V, additional, and Solomon, S D, additional

Published
2023
Full Text
View/download PDF

8. Association of CA-125 with markers of congestion, and effect of empagliflozin on CA-125 in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)

Author

Lee, M, primary, Welsh, P, additional, Berry, C, additional, Brooksbank, K J M, additional, Campbell, R T, additional, Docherty, K F, additional, Osmanska, J, additional, Roditi, G I L E S, additional, Wetherall, K, additional, Mcconnachie, A, additional, Mark, P B, additional, Mcmurray, J J V, additional, Jhund, P S, additional, Petrie, M C, additional, and Sattar, N, additional

Published
2023
Full Text
View/download PDF

9. Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER

Author

Kondo, T, primary, Vaduganathan, V, additional, Hernandez, A F, additional, Lam, C S P, additional, Inzucchi, S E, additional, Martinez, F A, additional, De Boer, R A, additional, Kosiborod, M N, additional, Desai, A S, additional, Kober, L, additional, Ponikowski, P, additional, Sabatine, M S, additional, Shah, S J, additional, Solomon, S D, additional, and Mcmurray, J J V, additional

Published
2023
Full Text
View/download PDF

11. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF

Author

Adamson, C, primary, Welsh, P, additional, Morrow, D A, additional, Docherty, K F, additional, Hammarstedt, A, additional, Inzucchi, S E, additional, Kober, L, additional, Kosiborod, M N, additional, Martinez, F A, additional, Ponikowski, P, additional, Sabatine, M S, additional, Solomon, S D, additional, Sattar, N, additional, Jhund, P S, additional, and McMurray, J J V, additional

Published
2022
Full Text
View/download PDF

12. History of stroke in patients with heart failure: prevalence, baseline characteristics and clinical outcomes

Author

Yang, M, primary, Kondo, T, additional, Butt, J H, additional, Abraham, W T, additional, Desai, A S, additional, Kober, L, additional, Martinez, F A, additional, Packer, M, additional, Pfeffer, M A, additional, Rouleau, J L, additional, Solomon, S D, additional, Zile, M R, additional, Jhund, P S, additional, and McMurray, J J V, additional

Published
2022
Full Text
View/download PDF

13. Prognostic importance of NT-proBNP following high-risk myocardial infarction in the PARADISE-MI Trial

Author

Jering, K, primary, Claggett, B, additional, Pfeffer, M A, additional, Granger, C, additional, Kober, L, additional, Lewis, E F, additional, Maggioni, A P, additional, Mann, D L, additional, McMurray, J J V, additional, Prescott, M F, additional, Rouleau, J L, additional, Solomon, S D, additional, Steg, P G, additional, Von Lewinski, D, additional, and Braunwald, E, additional

Published
2022
Full Text
View/download PDF

17. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF

Author

Yeoh, S E, primary, Docherty, K F, additional, Jhund, P S, additional, Hammarstedt, A, additional, Inzucchi, S E, additional, Kober, L, additional, Kosiborod, M N, additional, Martinez, F A, additional, Ponikowski, P, additional, Solomon, S D, additional, Sattar, N, additional, Welsh, P, additional, Sabatine, M S, additional, Morrow, D A, additional, and McMurray, J J V, additional

Published
2022
Full Text
View/download PDF

18. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model

Author

Kondo, T, primary, Jhund, P S, additional, Abraham, W T, additional, Rouleau, J L, additional, Packer, M, additional, Desai, A S, additional, Kober, L V, additional, Solomon, S D, additional, Zile, M R, additional, Inzucchi, S E, additional, Kosiborod, M N, additional, Sabatine, M S, additional, Ponikowski, P, additional, Martinez, F, additional, and McMurray, J J V, additional

Published
2022
Full Text
View/download PDF

19. Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials

Author

Adamson, C, primary, Butt, J H, additional, Rouleau, J, additional, Abraham, W, additional, Desai, A, additional, Dickstein, K, additional, Kober, L, additional, Lefkowitz, M P, additional, Packer, M, additional, Petrie, M C, additional, Swedberg, K, additional, Solomon, S D, additional, Zile, M, additional, Jhund, P S, additional, and McMurray, J J V, additional

Published
2022
Full Text
View/download PDF

21. Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: results of the global congestive heart failure research program

Author

Johansson, I, primary, Balasubramanian, K, additional, Bangdiwala, S, additional, Mielniczuk, L, additional, Hage, C, additional, Sharma, S K, additional, Branch, K, additional, Yonga, G, additional, Kragholm, K, additional, Sliwa, K, additional, Roy, A, additional, Stork, S, additional, McMurray, J J V, additional, Conen, D, additional, and Yusuf, S, additional

Published
2022
Full Text
View/download PDF

22. Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials

Author

Singh, A K, primary, Acharya, A, additional, Carroll, K, additional, Lopes, R D, additional, McCausland, F R, additional, Mulloy, L, additional, Perkovic, V, additional, Solomon, S, additional, Waikar, S S, additional, Wanner, C, additional, Wong, M G, additional, Cobitz, A R, additional, Mallett, S A, additional, Shaddinger, B C, additional, and McMurray, J J V, additional

Published
2022
Full Text
View/download PDF

24. A comprehensive study of the incremental prognostic value of novel biomarkers in PARADIGM-HF (Bio-PREDICT-HF)

Author

McDowell, K, primary, Simpson, J, additional, Jhund, P S, additional, Abraham, W T, additional, Claggett, B, additional, Cunningham, J, additional, Desai, A S, additional, Kober, L, additional, Prescott, M, additional, Rouleau, J L, additional, Swedberg, K, additional, Zile, M R, additional, Solomon, S D, additional, Packer, M, additional, and McMurray, J J V, additional

Published
2022
Full Text
View/download PDF

25. Trajectory of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction and association with cardiac structure and function

Author

Platz, E, primary, Claggett, B, additional, Jering, K S, additional, Kovacs, A, additional, Cikes, M, additional, Winzer, E B, additional, Rad, A, additional, Lefkowitz, M, additional, Gong, J, additional, Kober, L, additional, McMurray, J J V, additional, Solomon, S D, additional, and Shah, A, additional

Published
2022
Full Text
View/download PDF

27. Implications of the 2021 CKD-EPI cystatin C/creatinine eGFR equation for eligibility for therapy in HFrEF: insights from PARADIGM-HF

Author

Tolomeo, P, primary, Kondo, T, additional, Butt, J H, additional, Desai, A S, additional, Lefkowitz, M P, additional, Rouleau, J L, additional, Solomon, S D, additional, Swedberg, K, additional, Zile, M R, additional, Campo, G, additional, Jhund, P S, additional, Packer, M, additional, and McMurray, J J V, additional

Published
2022
Full Text
View/download PDF

30. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

Author

Cikes M., Planinc I., Claggett B., Cunningham J., Milicic D., Sweitzer N., Senni M., Gori M., Linssen G., Shah S. J., Packer M., Pfeffer M., Zile M. R., Anand I., Chiang L. -M., Lam C. S. P., Redfield M., Desai A. S., McMurray J. J. V., Solomon S. D., Cikes, M, Planinc, I, Claggett, B, Cunningham, J, Milicic, D, Sweitzer, N, Senni, M, Gori, M, Linssen, G, Shah, S, Packer, M, Pfeffer, M, Zile, M, Anand, I, Chiang, L, Lam, C, Redfield, M, Desai, A, Mcmurray, J, and Solomon, S

Subjects
heart failure with preserved ejection fraction, heart failure outcome, sacubitril/valsartan, echocardiography, atrial fibrillation
Abstract

Objectives: In this study, the authors sought to assess the relationship between AFF and outcomes, the treatment response to sacubitril/valsartan and first-detected AFF in patients with HFpEF enrolled in the PARAGON-HF trial. Background: Atrial fibrillation and flutter (AFF) are common in heart failure with preserved ejection fraction (HFpEF) and increase the risk of adverse outcomes. Methods: A total of 4,776 patients formed 3 groups: those with AFF according to electrocardiography (ECG) at enrollment (n = 1,552; 33%), those with history of AFF but without AFF on ECG at enrollment (n = 1,005; 21%), and those without history of AFF or AFF on ECG at enrollment (n = 2,219, 46%). We assessed outcomes, treatment response to sacubitril/valsartan in each group, and the risk associated with first-detected AFF in patients without any known AFF. The primary outcome was a composite of total heart failure hospitalizations and cardiovascular death. Results: History of AFF and AFF at enrollment were associated with higher risk of the primary outcome (risk ratio [RR]: 1.36 [95% CI: 1.12-1.65] and RR: 1.31 [1.11-1.54], respectively), than no AFF. Neither history of AFF nor AFF at enrollment modified the treatment effect of sacubitril/valsartan. Post randomization AFF occurred in 12% of patients without previous AFF and was associated with 2.8-fold higher risk of the primary outcome, but it was not influenced by sacubitril/valsartan. Conclusions: History of AFF and AFF on ECG at enrollment were associated with a higher risk of the primary outcome. First-detected AFF was not influenced by sacubitril/valsartan, yet it was associated with increased risk of all subsequent outcomes and may represent a potential target for future HFpEF trials. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711)

Published
2022

31. Daprodustat for the treatment of anemia in patients not undergoing dialysis

Author

Singh A. K., Carroll K., McMurray J. J. V., Solomon S., Jha V., Johansen K. L., Lopes R. D., Macdougall I. C., Obrador G. T., Waikar S. S., Wanner C., Wheeler D. C., Wiecek A., Blackorby A., Cizman B., Cobitz A. R., Davies R., DiMino T. L., Kler L., Meadowcroft A. M., Taft L., Perkovic V., Manunta P., Singh, A. K., Carroll, K., Mcmurray, J. J. V., Solomon, S., Jha, V., Johansen, K. L., Lopes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., Wanner, C., Wheeler, D. C., Wiecek, A., Blackorby, A., Cizman, B., Cobitz, A. R., Davies, R., Dimino, T. L., Kler, L., Meadowcroft, A. M., Taft, L., Perkovic, V., and Manunta, P.

Subjects
Male, Glycine, Myocardial Infarction, Anemia, General Medicine, Middle Aged, Hypoxia-Inducible Factor-Proline Dioxygenases, Intention to Treat Analysis, Stroke, Hemoglobins, Cardiovascular Diseases, Barbiturates, Hematinics, Humans, Darbepoetin alfa, Female, Renal Insufficiency, Chronic, Aged
Abstract

Background: \ud Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In patients with chronic kidney disease (CKD) who are not undergoing dialysis, the efficacy and safety of daprodustat, as compared with the conventional erythropoiesis-stimulating agent darbepoetin alfa, are unknown.\ud \ud Methods:\ud In this randomized, open-label, phase 3 trial with blinded adjudication of cardiovascular outcomes, we compared daprodustat with darbepoetin alfa for the treatment of anemia in patients with CKD who were not undergoing dialysis. The primary outcomes were the mean change in the hemoglobin level from baseline to weeks 28 through 52 and the first occurrence of a major adverse cardiovascular event (MACE; a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke).\ud \ud Results: \ud Overall, 3872 patients were randomly assigned to receive daprodustat or darbepoetin alfa. The mean (±SD) baseline hemoglobin levels were similar in the two groups. The mean (±SE) change in the hemoglobin level from baseline to weeks 28 through 52 was 0.74±0.02 g per deciliter in the daprodustat group and 0.66±0.02 g per deciliter in the darbepoetin alfa group (difference, 0.08 g per deciliter; 95% confidence interval [CI], 0.03 to 0.13), which met the prespecified noninferiority margin of −0.75 g per deciliter. During a median follow-up of 1.9 years, a first MACE occurred in 378 of 1937 patients (19.5%) in the daprodustat group and in 371 of 1935 patients (19.2%) in the darbepoetin alfa group (hazard ratio, 1.03; 95% CI, 0.89 to 1.19), which met the prespecified noninferiority margin of 1.25. The percentages of patients with adverse events were similar in the two groups.\ud \ud Conclusions: \ud Among patients with CKD and anemia who were not undergoing dialysis, daprodustat was noninferior to darbepoetin alfa with respect to the change in the hemoglobin level from baseline and with respect to cardiovascular outcomes. (Funded by GlaxoSmithKline; ASCEND-ND ClinicalTrials.gov number, NCT02876835.

Published
2021

34. A meta-analysis of echocardiographic measurements of the left heart for the development of normative reference ranges in a large international cohort: the EchoNoRMAL study

Author

Doughty, R. N., Gardin, J. M., Hobbs, F. D. R., McMurray, J. J. V., Nagueh, S. F., Poppe, K. K., Senior, R., Thomas, L., Whalley, G. A., Aune, E., Brown, A., Badano, L. P., Cameron, V., Chadha, D. S., Chahal, N., Chien, K. L., Daimon, M., Dalen, H., Detrano, R., Akif Duzenli, M., Ezekowitz, J., de Simone, G., Di Pasquale, P., Fukuda, S., Gill, P. S., Grossman, E., Hobbs, F. D. R., Kim, H. –K., Kuznetsova, T., Leung, N. K. W., Linhart, A., McDonagh, T. A., McGrady, M., McMurray, J. J. V., Mill, J. G., Mogelvang, R., Muiesan, M. L., Ng, A. C. T., Ojji, D., Otterstad, J. E., Petrovic, D. J., Poppe, K. K., Prendergast, B., Rietzschel, E., Schirmer, H., Schvartzman, P., Senior, R., Simova, I., Sliwa, K., Stewart, S., Squire, I. B., Takeuchi, M., Thomas, L., Whalley, G. A., Altman, D., Perera, R., Poppe, K. K., Triggs, C. M., Au Yeung, H., Beans Picón, G. A., Poppe, K. K., and Whalley, G. A.

Published
2014
Full Text
View/download PDF

39. Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA

Author

Abdul-Rahim, A. H., Fulton, R. L., Frank, B., McMurray, J. J. V., Lees, K. R., Alexandrov, A. V., Bath, P. W., Bluhmki, E., Claesson, L., Curram, J., Davis, S. M., Donnan, G., Diener, H. C., Fisher, M., Gregson, B., Grotta, J., Hacke, W., Hennerici, M. G., Hommel, M., Kaste, M., Lyden, P., Marler, J., Muir, K., Sacco, R., Shuaib, A., Teal, P., Wahlgren, N. G., Warach, S., and Weimar, C.

Published
2015
Full Text
View/download PDF

40. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

Author

Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., and Fang, J. C.

Subjects
*HEART failure, *VENTRICULAR ejection fraction, *HEART failure patients, *DAPAGLIFLOZIN, *SODIUM-glucose cotransporter 2 inhibitors, CARDIOVASCULAR disease related mortality
Abstract

BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitaliza-tion for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain. METHODS We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovas. cular death, as assessed in a time-to-event analysis. RESULTS Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients (19.5%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.92; P<0.001). Worsening heart failure occurred in 368 patients (11.8%) in the dapagliflozin group and in 455 patients (14.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.69 to 0.91); cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05). Total events and symptom burden were lower in the dapagliflozin group than in the placebo group. Results were similar among patients with a left ventricular ejection fraction of 60% or more and those with a left ventricular ejection fraction of less than 60%, and results were similar in prespecified subgroups, including patients with or without diabetes. The incidence of adverse events was similar in the two groups. CONCLUSIONS Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.) [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Cost Effectiveness Of Lowering Cholesterol [with Reply]

Author

Shepherd, J., McMurray, J. J. V., Morrison, C. E., Haycox, Alan, Barton, Stuart, Walley, Tom, Wierzbicki, A. S., Reynolds, T. M., Masters, Paul, Shetty, Arun, Robertson, Michael, Pharoah, P. D. P., and Hollingworth, W.

Published
1996

45. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Author

Teerlink, J. R., Diaz, R., Michael Felker, G., Mcmurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sorensen, T., Bohm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlstrom, U., Echeverria, L. E., Fang, J. C., Filippatos, G., Fonseca, C., Goncalvesova, E., Goudev, A. R., Howlett, J. G., Lanfear, D. E., Li, J., Lund, M., Ambrosio, G., Carluccio, E., Macdonald, P., Mareev, V., Momomura, S., O'Meara, E., Parkhomenko, A., Ponikowski, P., Ramires, F. J. A., Serpytis, P., Sliwa, K., Spinar, J., Suter, T. M., Tomcsanyi, J., Vandekerckhove, H., Vinereanu, D., Voors, A. A., Yilmaz, M. B., Zannad, F., Sharpsten, L., Legg, J. C., Varin, C., Honarpour, N., Abbasi, S. A., Malik, F. I., Kurtz, C. E., and Cardiovascular Centre (CVC)

Subjects
Cardiac function curve, Male, medicine.medical_specialty, animal structures, Cardiotonic Agents, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Cardiac Myosins, Internal medicine, medicine, 80 and over, Humans, Urea, 030212 general & internal medicine, Aged, Aged, 80 and over, Heart Failure, Ejection fraction, business.industry, Cardiac myosin, Stroke Volume, General Medicine, Stroke volume, Middle Aged, medicine.disease, R1, Myocardial Contraction, 3. Good health, Omecamtiv mecarbil, Cardiovascular Diseases, Heart failure, cardiovascular system, Cardiology, Female, business, Heart Failure, Systolic, Systolic
Abstract

From: New England Journal of Medicine, Teerlink, JR, Diaz, R, Felker, G, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure, 384(2):105-116. Copyright © 2020. Massachusetts Medical Society. Reprinted with permission. [Abstract] BACKGROUND. The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS. We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS. During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P=0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro–B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS. Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.)

Published
2020

48. P6193Dalcetrapib reduces incident diabetes in patients with recent acute coronary syndrome

Author

Schwartz, G, primary, Leiter, L A, additional, Ballantyne, C M, additional, Barter, P J, additional, Black, D M, additional, Kallend, D, additional, Leitersdorf, E, additional, McMurray, J J V, additional, Nicholls, S J, additional, Olsson, A G, additional, Preiss, D, additional, Shah, P K, additional, Tardif, J C, additional, and Kittelson, J, additional

Published
2019
Full Text
View/download PDF

49. P2630Incidence and prognostic impact of new-onset left bundle branch block in patients with heart failure and reduced ejection fraction

Author

Kristensen, S L, primary, Roerth, R, additional, Jhund, P S, additional, Beggs, S, additional, Kober, L, additional, Abraham, W T, additional, Desai, A, additional, Solomon, S, additional, Packer, M, additional, Rouleau, J, additional, Zile, M, additional, Dickstein, K, additional, Petrie, M C, additional, and McMurray, J J V, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results